This contract opportunity involves establishing a non-exclusive discount agreement for the medication Omalizumab (ATC Code: R03DX05) in Germany. The contract will be effective from December 1, 2024, to November 30, 2026, with the option for suppliers to enter into the contract at any time during thi
Tender closed on 27 Sept 2026. Awaiting award.
This contract opportunity involves establishing a non-exclusive discount agreement for medications containing the active ingredient Teriparatide (ATC Code: H05AA02). The contract will be effective from December 1, 2025, to November 30, 2027, with the option for suppliers to enter into the contract a
This contract opportunity involves the establishment of non-exclusive discount agreements for the drug Trastuzumab, classified under ATC code L01FD01, in the regions of Lower Saxony, Bremen, and Saxony-Anhalt. The focus is on parenteral preparations made from finished medicinal products for oncology
Develop medical countermeasures for CBRN threats with up to £4 million funding over 30 months, from prototype through Phase 2a clinical studies.
A three-year funded fellowship helping healthcare professionals with PhDs return to clinical research after extended career breaks.
Opportunity to provide a digital mental health platform delivering NICE-recommended therapeutic interventions and resources for children, young people, and families in South Staffordshire.
Opportunity for Primary Care Networks to deliver integrated COPD identification and specialist support services using digital risk stratification across Hull and East Yorkshire communities.
